Fragments of the human immunodeficiency virus (HIV) envelope coding region have been fused with the hepatitis B virus envelope middle protein. In this system, HIV antigenic determinants are exposed at the surface of a highly antigenic structure, the hepatitis B surface antigen particle. Immunization of rabbits with these particles elicited antibodies directed against both parts of the hybrid protein. One of the rabbit antisera not only exhibited a neutralizing effect on the original HIVi isolate but also on a divergent Zairian isolate. The HIV sequence in this recombinant is 84 amino acids long and contains conserved and variable domains and a region critical for interaction with the CD4 receptor. Such recombinant antigens could be primary elements in the design of a polyvalent vaccine.
The human immunodeficiency virus (HIV) is the etiologic agent for acquired immunodeficiency syndrome (AIDS), which has now reached epidemic proportions. A vaccine against AIDS as well as an effective treatment of the disease is urgently needed. Logical candidates for such a vaccine are surface proteins associated with the viral envelope. These are derived from a precursor, gpl60, that is proteolytically cleaved to generate the external envelope glycoprotein gp120 and the transmembrane envelope glycoprotein gp4l (1, 2) . gp120 contains conserved and variable regions, and up to 30% of amino acid divergence is observed between different HIV isolates (3, 4) . Purified gpl20 has been shown to bind cell receptor CD4 (5) and to elicit neutralizing antibodies in immunized animals (6) . Recombinant proteins that contain portions ofgpl20 have been produced in mammalian cells (7) and in Escherichia coli (8) . Synthetic peptides, fragments of the envelope protein, have also raised modest neutralizing titers when used as immunogens (9) . Anyway, the antibodies induced by the native envelope protein are not protective in vivo. The variability of gp120 is also an obvious problem in vaccine development.
To overcome these obstacles, we chose to express conserved regions of the HIV envelope protein in a conformation that would enhance their immunogenicity.
We chose the hepatitis B surface antigen (HBsAg) particle as a vehicle for the presentation of HIV antigenic determinants. The surface proteins of hepatitis B virus (HBV) are the translational products of a large open reading frame, which is divided into three domains, each of which begins with an in-frame ATG codon that could be used as a translational initiation site. These domains are referred to as pre-S1, pre-S2, and S in their 5' to 3' order in the open reading frame defining three polypeptides referred to as major (S only), middle (pre-S2 plus S), and large proteins (pre-Si plus pre-S2 plus S) (10).
As we have reported previously, eukaryotic, cells transformed with a plasmid expression vector are able to synthesize and assemble a complex multimeric lipoprotein particle, the HBsAg particle (11). This particle is structurally similar to the empty viral envelope normally present in the serum of infected patients and is highly immunogenic upon injection into animals and humans.
To ensure a correct presentation of HIV antigenic determinants, they have been inserted within the pre-S2 part of the middle protein of HBsAg; this segment contains an immunodominant epitope (12) and a receptor site (13) and should be well exposed at the surface of the HBsAg particles. HBsAg particles containing 84 amino acids of HIV envelope were able to induce neutralizing antibodies against HIV1.
MATERIALS AND METHODS
Vector Construction. M13tg130 is a cloning vector derived from bacteriophage M13. It contains, in the 5' part of the ,8-galactosidase segment, 11 unique restriction sites (14) (Fig.   1 ). Insertion of exogenous DNA fragments into this polylinker may be detected by the abolition of coloration with 5-bromo-4-chloro-3-indolyl ,8-D-galactoside. Screening of the blue plaques by in situ hybridization allows the detection of in-phase DNA fragments.
The HBsAg expression vector pSVS (11) was modified to include a segment EcoRI/Sal I of M13tgl30 DNA containing 10 restriction sites between the EcoRI and Xho I site of HBV pre-S2 region. The fusion between Sal I and Xho I restriction sites restores the reading frame in the pre-S2 region. The resulting vector pM2S was subsequently deleted ofthe pre-S1 region and termed pSV2S. In this construction, the fusion between the cloned DNA and the S gene is directly under the control of simian virus 40 early promoter; HBV sequences downstream of the S gene allow polyadenylylation of HBsAg messenger RNA.
Transfection of Animal Cells. Chinese hamster ovary (CHO) dhfr-cells clone DXB11 (15) were maintained as monolayers in Ham's F-12 medium supplemented with 10% fetal calf serum. Cells were transfected by using the calcium phosphate procedure (16) with a glycerol shock 6 hr later. Cotransfection with pSV2 dhfr vector (17) 
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Immunoblots. About 1 ttg of purified recombinant particles was boiled in Laemmli sample buffer, separated by electrophoresis on a 12.5% NaDodSO4/polyacrylamide gel, and electrotransferred onto nitrocellulose filters (Schleicher & Schuell).
Proteins immobilized on filters reacted with different antisera: a-P49a (19), a rabbit anti-peptide antiserum specific for HBsAg, -and antisera directed against conserved regions of HIV1 gp160 (Fig. 2 ) raised in rabbits by using synthetic peptides coupled with bovine serum albumin. Finally, immunoreactive proteins were detected by anti-rabbit antibodies conjugated with peroxidase (Amersham) and revealed with diaminobenzidine.
Immunizations and Measurement of Antibody Production. Rabbits were immunized two times at a 1-month interval with intradermic injection of =4 Aug of purified HBsAg recombinant particles in Freund's complete adjuvant for the primary immunization and in Freund's incomplete adjuvant for the secondary immunization. Sera were obtained 30 days after the last injection.
Antisera were evaluated for antibodies in an ELISA, using solid-phase plasma-derived HBsAg particles (Hevac B vaccine) or HIV-related synthetic peptides (see Fig. 2 ). Synthetic peptides were provided by e. Rochat (Unitd Associde 553, Centre National de la Recherche Scientifique, Marseilles).
All antigens were used at a concentration of 1 Ag/ml on microtiter plates (Falcon Probind), and ELISAs were performed as described (20) .
Neutralizing Antibody Assay. For assessment of neutralizing antibody activity of the sera, we used stimulated human peripheral blood lymphocytes as cells susceptible to the HIV infection. Different stocks of LAVBRU isolate (21) were used as virus inoculum. Each serum dilution was preincubated with an equal volume of virus inoculum for 1 hr at 370C. The mixture was then added to 3 x 106 human peripheral blood lymphocytes in RPMI 1640 medium supplemented with 10% fetal calf serum containing 20 units of interleukin per ml, 2.2 ttg of Polybrene per ml, and 25 units of anti-interferon antiserum per ml. After 1 hr of incubation at 370C, the cells were rinsed and cultivated in complete RPMI medium. Supernatant was removed twice a week and the same dilutions of the tested sera were added in the new medium at the first two changes. Supernatants were frozen at -700C and assayed for reverse transcriptase (RT) activity (22) . RESULTS
Cloning of HIV Envelope Gene Fragments into the HBsAg
Eukaryotic Expression Vector. Randomly cut DNA fragments of the HIV genome, ranging from 50 to 1000 base pairs (bp), were cloned into the Sma I and EcoRV sites of the bacteriophage M13tgl30 (Fig. 1 ). In situ hybridization and sequencing permitted us to map the cloned fragment precisely in the HIV1 envelope coding region. The selected HIV fragments were then transferred into the HBsAg expression vector pSV2S (Fig. 1) . pSV2S is a modification of a previously described expression vector pSVS as detailed in Materials and Methods. In the pSV2S vector, we have deleted part of the pre-S2 region and replaced it with the M13tgl30 polylinker. In this construction, the polylinker allows insertion of a DNA fragment in-frame with the pre-S2 region and the S gene. Thus, any fragment cloned in-frame with the lacZ gene in bacteriophage M13tgl30 could be easily transferred in-frame with the S gene in the pSV2S expression vector.
Among the HIV envelope-related fragments cloned in M13tgl30, two were studied in more detail. Clone 2 contains a HIV insert of 54 bp (nucleotides 6439-6492), located in the middle part of the gpl20 coding sequence (Fig. 2) ; it covers a conserved region between HIV1 isolates (3).
Clone 8 contains a HIV insert of 252 bp (nucleotides 6915-7166), corresponding to the subcarboxyl-terminal part of the gpl20 protein (Fig. 2 ). This region is relatively well conserved among different isolates and presents homology with the constant region of the immunoglobulin heavy chain (23) . Furthermore, part of this DNA fragment encodes a domain involved in the binding of the gpl20 protein to the receptor of the virus, the CD4 molecule (24) .
Expression of the HIV-HBV Fusion Proteins in Transfected Cells. HBsAg expression vectors containing fragments of the HIV1 envelope gene were used to transfect CHO cells. Stable clones expressing HBsAg, as detected by an RIA specific for the HBV major envelope protein, were screened for expression of the heterologous gene by means of RNA dot blots. They were further characterized by northern blot analysis, using as probes either HIV or HBV DNA fragments. Hybrid messenger RNA was observed (data not shown). The secreted particles were purified from the cell culture supernatant by the procedure used for HBsAg particles (11 envelope determinants (Fig. 3) . The following results were observed.
Recombinant particle 2. In addition to the major protein of HBsAg p22 and its glycosylated counterpart gp26, the antip49a antiserum reveals four bands ranging from 27 to 32 kDa corresponding to the middle protein (Fig. 3A, lane 1) . These four bands were also strongly revealed by the serum raised against the homologous HIV1 related peptide (pep 5) (Fig.  3A, lane 2) . This demonstrates that the recombinant HBsAg particle 2 carries the foreign determinant. The amounts of middle and major proteins are about the same. The fused middle protein is present in four forms, which could represent as for the major protein different glycosylated forms.
Recombinant particle 8. The anti-p49a antiserum reveals the HBsAg major protein in its two forms (p22 and gp26) as well as a pattern of bands of molecular mass ranging from 33 to 46 kDa (Fig. 3B, lane 1) . Antisera raised against the two homologous peptides 6 and 7 revealed the same pattern of heavy proteins (Fig. 3B, lanes 2 and 3) , demonstrating the presence of HIV determinants in the particles. The amount of the fused middle protein is lower than the amount of major protein. The anti-peptide antisera raised against peptide chemically linked to bovine serum albumin also revealed a protein of 67 kDa, which corresponds to bovine serum albumin copurified with the HBsAg particles.
Humoral Immune Response to HBsAg Recombinant Particles. Rabbits were immunized two times at a 1-month interval with each of the different HBsAg recombinant particles (see Materials and Methods) . The specificity of the immune response was determined by ELISA with plasma-derived particles and different corresponding HIV1 peptides. Antisera were also tested against pre-S2 peptide (120-145 kDa) as a negative control ( Table 1) .
As expected, all rabbits developed an antibody response to native HBsAg particles. Recombinant 8 induced an antipeptide response directed against two different regions of the HIV sequence (peptides 6 and 7). The anti-peptide response induced by recombinant 2 is comparatively lower and does not correlate with the high proportion of fused protein present in these particles.
Immune Sera to Recombinant Particle 8 Neutralizes HIV Infection of Cells in Culture. Rabbits were immunized with purified HIV-HBsAg recombinant particles and the sera were assayed for their ability to neutralize LAV1BRU isolate (21) . In vitro viral infection of human peripheral blood lymphocytes was monitored by RT activity for 3-15 days. We based our assay on the reduction of RT activity by the immune serum compared to the preimmune serum of a particular rabbit.
Antibodies may not neutralize the virus efficiently if overwhelming quantities of infectious virions are present, so we assessed the ability of a 1:50 dilution of the antisera to neutralize different virus stocks (Fig. 4 A-C) . Serum of rabbits immunized with recombinant particle 8 completely neutralized the viral infectivity of the less infectious virus stock (Fig. 4A) , and we observed that RT activity decreases from 95% to 63% and 35% when we increase the infectivity of the virus stock (Fig. 4D) . This confirms that the neutralizing ability of the antisera is dependent on the amount of virus.
No reduction in RT activity was observed with antiserum from rabbits immunized with recombinant particle 2 even at a low concentration of virus inoculum (data not shown).
In addition, neutralization ofdifferent isolates of HIV1 was also examined by using a constant concentration of the virus [1000 TCID50 (50% tissue culture infective dose) per 3 x 106 cellules] with various dilutions of the antisera raised against recombinant particles 8. Fig. 5 shows a 50% reduction of LAVBRU isolate infectivity with the 1:50 dilution as comBiochemistry: Michel et al. Titers are expressed as reciprocal of the immune serum dilution that gives 3 times the optical density of preimmune serum at the same dilution. pared to the preimmune serum. We also assessed the neutralizing activity of this antiserum against a HIV1 Zairian isolate, LAVELI (3); a 50% neutralization effect could be observed at 1:25 dilution (Fig. 5) .
DISCUSSION
The external HIV envelope glycoprotein gp120, which is theoretically the prime target for a protective immune response toward HIV, contains conserved and variable regions. Conservation of sequences within the constant domains presumably indicates selective pressure to maintain sequences with potential functional importance. In this work, we have chosen to express two conserved regions of the HIV1 envelope as fusions with the HBsAg middle protein.
The HBsAg particle is a good immunogen in two respects: (i) it is a polymer of high molecular weight, carrying on its surface numerous copies of antigenic determinants; (ii) it carries also T epitopes, which could help the recognition of B epitopes by the immune system (25 (24); the other (clone 2) is unrelated to known biological activity.
The recombinant HIV-HBsAg particles obtained by fusion of these antigenic determinants within the pre-S2 region gene product have been studied by using antibodies raised against homologous synthetic peptides. Western blot analysis demonstrated that HIV antigenic determinants are present in the particles as fusion proteins.
The ratios between the fused protein and the major protein in the different recombinant particles are variable. In recombinant 8, the fused protein is less abundant, which could be related to the large size of the inserted sequence. The original size of the HBV pre-S2 translation product is 55 amino acids and in this construction is extended to 111 amino acids. The size of the fused protein could therefore hamper its insertion into the HBsAg particles.
In recombinant 2 (18 amino acids), the ratio between fused protein and major protein is high and comparable to that observed between the middle and major protein in particles obtained by transfection of the original HBsAg expression vector pSVS (11) .
Immunogenicity of the recombinant HIV-HBsAg particles was studied by immunization in rabbits. The humoral response is directed against the two antigenic regions and shows that the foreign epitopes are efficiently presented by the hybrid particles. The HIV determinants carried by recombinant 8 induced a better immune response than those carried by recombinant 2. According to the lower proportion of the fused protein in recombinant 8 (29) , using a fused protein produced in E. coli carrying an overlapping sequence, also obtained neutralizing antibodies and a specific cellular immune response. In our HBsAg expression system, the proteins are normally glycosylated and this could be very important in eliciting high-affinity antibodies needed to block the interaction of the HIV envelope protein with the CD4 receptor. Moreover, this HIV antigenic determinant could be better presented to the immune system than in the native gp120 viral protein. The less efficient neutralization of the Zairian isolate (LAVELI) could be explained by an amino acid sequence variation of -30% in one of the regions critical for virus-CD4 interaction (24) .
Antibodies to recombinant 2 were also assayed in neutralization assays. The HIV sequence carried by recombinant 2 does not induce neutralizing antibodies in these experiments. A weak immune response of these animals or a poor immunogenicity of this region could account for this result.
In summary, we have constructed a potent system for the presentation of foreign antigenic determinants of the HIV envelope that has enabled us to obtain neutralizing antibodies directed against an envelope protein region, which may be poorly immunogenic or may not be so well presented in the native protein. Moreover, juxtaposition of HBV and HIV antigenic determinants at the surface of the same immunogenic particle could lead to polyvalent vaccines.
